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Abstract: LRRK2 mutations have recently been described in
families with Parkinson’s disease. Here we show that one of
them (G2019S) is present in 6% (7 of 124) unrelated cases
of disease in a clinic-based sample series from central Por-
tugal, but not present in 126 controls from the same pop-
ulation. Thus, LRRK2 mutations appear to be a common
cause of typical Parkinson’s disease and as such will alter
clinical practice. © 2005 Movement Disorder Society
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While Parkinson’s disease (PD) is conventionally
thought of as a sporadic disease and considerable effort
has been expended to find environmental risk factors,
over the past 8 years the role of genetic factors has
clearly been shown to be of major importance. Mutations
in -synuclein have been shown to cause autosomal
dominant PD,1 and mutations in parkin, DJ-1, and
PINK1 have been shown to cause early-onset Parkinson-
ism in a recessive fashion.2–4 However, all these muta-
tions are comparatively rare and none of them have had
a widespread impact on clinical practice.5
Recently, mutations in LRRK2, encoding the protein
dardarin, were identified as causes for autosomal domi-
nant PD.6,7 A series of point mutations has been subse-
quently described in families with clinical phenotypes
ranging from typical Parkinson’s disease to very atypical
Parkinsonisms.6–13 In our screening of families with Par-
kinson’s disease for mutations, two have shown up more
than once. These are R1441G (formerly reported as
R1396G,6 revised codon numbering based on accession
number AY792511; all codon and exon numbering here
based on AY792511), identified in several Basque pa-
tients,6 and G2019S, identified in several popula-
tions.9–13 We determined to test for these two mutations
in a series of patients with Parkinson’s disease, which we
identified in the Movement Disorders Clinic at the Co-
imbra University Hospital in central Portugal.
PATIENTS AND METHODS
One hundred twenty-eight cases of clinically typical
Parkinson’s disease were collected at the Movement
Disorders Clinic at the Coimbra University Hospital.
This is a consecutive clinic case series comprised of
patients who gave permission for sampling. The patients
were all Caucasian and of apparent Portuguese ancestry,
although a detailed genealogical history outside of the
nuclear family was not taken. In this clinic, more than
90% of cases consent for blood sampling. The control
series, which was from the same region, largely con-
sisted of spouses of affected individuals. The criteria for
Parkinson’s disease diagnosis were the United Kingdom
Brain Bank Criteria.14 The clinical PD evaluation was
done using Unified Parkinson’s Disease Rating Scale
(UPDRS) and Hoehn and Yahr scale. All the cases were
diagnosed with levodopa-responsive Parkinson’s disease
by a neurologist with experience in PD. A summary of
the clinical features of the case series is given in Table 1.
All control individuals were examined by a neurologist
and were found to be free of any movement disorder or
neurodegenerative disease. Mini-Mental State Examina-
tion (MMSE) was used as a screening test and no other
cognitive test was performed. MMSE scores used for the
diagnosis are less than 15 for individuals who never went
to school, less than 22 for individuals with 1 to 11 years
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of school, and less than 27 for individuals with more than
11 years of school.
DNA Sequencing
After obtaining informed consent, approved by the
Coimbra University Hospital Ethical Committee, a 10 ml
blood sample was taken and DNA was extracted by
standard procedures. For sequencing, exons 31 and 41 of
all the case and control DNA were PCR-amplified from
the genomic sample using primers 5-TCAACAGGA-
ATGTGAGCAGG-3/5-CCCACAATTTTAAGTGAG-
TTGC-3 and 5-TTTTGATGCTTGACATAGTGGAC-3/
5-CACATCTGAGGTCAGTGGTTATC-3, respectively.
In addition, we sequenced all 51 exons of the gene in
16 of the familial cases using primers previously de-
scribed for exons 1–5 and 7–51 and forward primer
5-GGAAGGGCTGCTTCACAGAAAT -3 and reverse
primer 5-GAATGGGTTGAGCATCCACAAG-3 for
exon 6.6 In all cases, the products were sequenced using
the same forward and reverse primers with Applied Bio-
systems BigDye terminator and run on an ABI3100
genetic analyzer as per the manufacturer’s instructions
(Applied Biosystems, Foster City, CA). The sequences
were analyzed with Sequencher software (Genecodes,
Ann Arbor, MI).
RESULTS
In our series of 128 consecutive patients, 11 (9%) had
the G2019S mutation; none had the R1441G mutation.
The mutations occurred in five sporadic cases of disease
and in two families. Discounting the secondary cases in
these families, the mutation prevalence in probands is
7/124 (6%). In addition, our sequencing of the rest of the
gene in a subset of familial disease failed to identify
other mutation carriers. The mutation-positive patients
presented with an akinetic-rigid syndrome (n  5) or a
tremor-predominant disease (n  6). In both families
with the G2019S mutation, the mutation occurred in all
three affected family members who had attended the
clinic together. In Family A (Fig. 1), both parents in this
kindred were apparently healthy and by history died of
nonneurological disease in their 80s. The three individ-
uals are siblings and appear to be the only affected family
members. Two of the patients show an akinetic-rigid
syndrome while the other presented with resting tremor.
Two individuals also had cognitive impairment begin-
ning after their parkinsonian syndrome. Family members
A2 and A3 showed cognitive decline (MMSE scores 22
and 13, respectively). In the second family, two of the
mutation carriers (B2 and B3) presented with painful
cervical dystonia, which was responsive to levodopa, and
neither showed tremor or dementia. In this family, the
parents died at ages 69 and 80 without neurological
illness according to the family report. For the five spo-
radic cases, parental mortality information was available
for three of them. In two, the father died at less than 55
years and the mother died at 70 years; in the third, both
parents died at an age greater than 70. It is worth noting
that the case with the youngest age of onset (38 years) is
an identical twin, whose twin remains clinically unaf-
fected. Neither of the families and none of the sporadic
cases are known to be related to each other, nor did they
come from the same villages. Thus, there is no sugges-
tion that these individuals share a recent founder. In
TABLE 1. Clinical features of Portuguese patients studied
Characteristic
Subjects
(n  128)
Mutation carriers
(n  11)
Age at collection
(mean  SD) 67.2  10.3 67  7.7
Age at onset (mean
 SD) 57.1  12.0 54.8  9.5
Range of age at onset 30–84 38–68
Other features
Dystonia (non drug
induced) 27 (0.21) 5 (0.45)
Dementia 15 (0.15) 2 (0.18)
Essential tremor 6 (0.04) 0 (0.0)
Family history
Positive 26 (0.20) 6 (0.54)
Negative 102 (0.80) 5 (0.45)
Affected relatives (n)
1 20 (0.81) 0 (0.0)
2 4 (0.15) 2 (0.18)
3 1 (0.04) 0 (0.0)
3 1 0 (0.0)
Values are expressed as n (frequency), unless otherwise indicated.
FIG. 1. Families A and B, positive for LRRK2 G2019S mutation. All
affected family members are carriers of the mutation. AO, age at onset;
A, current age.
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addition, though the ethnic background of the two fam-
ilies from the United States is not known,12 there is no
hint of Portuguese ancestry; rather, German and Irish are
discussed as the likely ethnic backgrounds.
DISCUSSION
The pathogenicity of the G2019S is clear for three
reasons. First, our previous data showed segregation of
this mutation in two families from North America. Sec-
ond, the limited segregation in the two families we have
examined also shows segregation of mutation with dis-
ease. Third, we did not find this mutation in controls in
our control series here, nor have we found this variant in
more than 1,500 control subjects from North America
(data not shown).9
These data are remarkable and of clinical importance
for the simple reason that they show that a high propor-
tion of clinically typical Parkinson’s disease in this pop-
ulation, as in the Basque population,6 carries a patho-
genic mutation. Many of these cases do not have familial
disease, and, given the information from the two familial
cases, the likely reason for this nonpenetrance even at
high age in the parents is unclear. These findings will
have an impact on clinical practice. Neurologists treating
Parkinson’s disease have usually assured their patients
that the disease was not genetic in etiology and certainly
have not routinely suggested genetic testing. These data
suggest that this widespread advice and practice will
have to change. A large proportion of cases, certainly
from Portugal and from the Basque country, carry mu-
tations that put their family members at very high risk for
disease, although the likely ages of onset are extremely
difficult to predict. This latter fact is underscored by the
finding that the identical twin of one of the sporadic
mutation carriers remains unaffected 24 years after the
onset in his brother, demonstrating that, even in this
autosomal dominant disorder, environmental or stochas-
tic factors play an important role in determining the age
of onset. Putting these data into clinical practice will
entail education of both clinicians and patients and also
the inclusion of more genetic counselors in movement
disorders practices. On the positive side, the identifica-
tion of these patients offers the prospect of better and
earlier diagnosis and thus of more effective clinical prac-
tice.
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